Population Pharmacokinetics of Continuous-Infusion Meropenem in Febrile Neutropenic Patients with Hematologic Malignancies: Dosing Strategies for Optimizing Empirical Treatment against Enterobacterales and <i>P. aeruginosa</i>
A population pharmacokinetic analysis of continuous infusion (CI) meropenem was conducted in a prospective cohort of febrile neutropenic (FN) patients with hematologic malignancies. A non-parametric approach with Pmetrics was used for pharmacokinetic analysis and covariate evaluation. Monte Carlo si...
Main Authors: | Pier Giorgio Cojutti, Anna Candoni, Davide Lazzarotto, Carla Filì, Maria Zannier, Renato Fanin, Federico Pea |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2020-08-01
|
Series: | Pharmaceutics |
Subjects: | |
Online Access: | https://www.mdpi.com/1999-4923/12/9/785 |
Similar Items
-
Evaluating the use of meropenem in hematologic patients with febrile neutropenia
by: R.A. Stuurman, et al.
Published: (2023-10-01) -
Measuring Creatinine Clearance Is the Most Accurate Way for Calculating the Proper Continuous Infusion Meropenem Dose for Empirical Treatment of Severe Gram-Negative Infections among Critically Ill Patients
by: Carla Troisi, et al.
Published: (2023-02-01) -
Successful Treatment of Bacteremia and Ventilator-Associated Pneumonia Caused by KPC/OXA-48-like <i>Klebsiella pneumoniae</i> Co-Producer with a Continuous Infusion of High-Dose Meropenem Plus Fosfomycin Guided by Real-Time Therapeutic Drug Monitoring
by: Pier Giorgio Cojutti, et al.
Published: (2022-01-01) -
Extended Infusion of Meropenem in Neonatal Sepsis: A Historical Cohort Study
by: Guangna Cao, et al.
Published: (2022-03-01) -
Use of cefepime, meropenem, or piperacillin/tazobactam as initial treatment for febrile neutropenia in patients with hematological malignancy — a real-life experience
by: Najmul Karim, et al.
Published: (2022-08-01)